Boston – Jan 7, 2025
Strengthening AI-Driven Innovation in Small Molecules and ADCs
Pfizer has expanded its partnership with AI-driven drug discovery company PostEra, marking the second time the two firms have extended their collaboration since it began in 2020. The latest agreement increases the deal’s value to $610 million and adds antibody-drug conjugates (ADCs) to the scope of their joint efforts. While specific results have not yet been disclosed, the move reflects Pfizer’s confidence in PostEra’s AI-based platform, Proton, which blends machine learning with synthesis-aware design tools to streamline drug candidate development.
AI-Powered Drug Discovery for Oncology and Infectious Diseases
Pfizer initially partnered with PostEra to create a generative chemistry platform for accelerating small molecule discovery. In 2021, the collaboration evolved into an AI Lab dedicated to oncology drug development and antiviral therapies for COVID-19. The synergy of Pfizer’s biological data and PostEra’s machine learning capabilities aims to enhance the efficiency and pace of drug discovery.
Scaling Research with Additional Small Molecule Targets and ADCs
As the prior agreement reached its limit on program nominations, this expansion introduces new small molecule targets and ventures into ADC research. PostEra’s platform will be used to improve payloads and linker designs—critical components in targeted cancer therapies—further boosting precision and effectiveness.
Financial Commitments and AI Validation in Drug Development
Under the updated terms, PostEra will receive a $12 million upfront payment. This builds on a previous $13 million upfront payment and performance-based milestone eligibility of up to $248 million. The collaboration is supported by peer-reviewed research validating AI’s ability to accelerate preclinical progress, demonstrating the increasing impact of AI in pharmaceutical R&D.
This partnership strengthens Pfizer’s position in AI-driven therapeutic innovation by embedding machine learning into its broader R&D strategy.
“The broadened partnership builds on peer-reviewed publications with Pfizer validating the real-world impact of AI-driven drug discovery in hitting preclinical milestones faster than anticipated,” said Alpha Lee, Chief Scientific Officer at PostEra.
About PostEra AI
PostEra is a next-generation biopharmaceutical company focused on AI-powered medicinal chemistry. Its proprietary platform, Proton, accelerates drug discovery both internally and through partnerships. The company has secured over $1 billion in AI-based collaborations with major firms like Pfizer and Amgen. PostEra also leads an antiviral drug discovery center for pandemic preparedness, funded by one of the largest NIH grants on record. By integrating AI and machine learning, PostEra is redefining how quickly life-saving therapies reach patients.
More about this news
By